Swiss life sciences solutions firm Lonza has been contracted by US biotechnology group Elusys Therapeutics to produce Anthim, its late stage Ab candidate treatment for anthrax infection.
ExcellGene’s OrbShake 250L mammalian cell culture bioreactor has equalled biomass productivity and oxygenation levels previously only achieved by traditional stirred tank systems.
Artelis president Jose Castilo believes that the record MAb yield from CHO cells grown in its iCELLis bioreactor shows the platform could shift the paradigm for the "production of recombinant proteins.”
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from innovatis, Stäubli, GE and Sterilin.
Baxter has successfully produced H5N1 influenza vaccine in African
green monkey kidney cells in quantities sufficient for clinical
testing, according to an article published in The New England
Journal of Medicine.
A new consortium in Scotland is to develop a new 3D cell assay for
use in drug discovery and for safety evaluation prior to clinical
trials, in the hope of cutting costs and reducing the use of
animals for testing.
Swiss supplier and services provider Lonza has added another
product to its catalogue of cell culture media, the most recent
addition to the offering of its new bioscience unit.
French firm Vivalis has announced the first data evaluating its
proprietary EBx cell lines for the production of monoclonal
antibodies (MAbs), with initial results suggesting high cytotoxic
properties in the resultant MAbs.
Research into new tools that will remove the need to use animals in
medical research has received a £240,000 (€356,000) boost at the
University of Nottingham.
Just weeks after announcing intentions to snap up biologics firm
MedImmune, AstraZeneca has acquired DSM's old biologics
manufacturing facility in Montreal, Canada, a site that's been
gathering dust since it was mothballed...
A firm specialising in disposable equipment for the
biopharmaceutical industry has introduced a new revamped bioreactor
to its catalogue, dispensing with the traditional rocking and
rolling mechanisms used in many bioreactors.
The first step towards true in-line glucose monitoring for cell
culture bioprocesses has been made that will allow greater control
over the bioprocess manufacturing.
Tecan has made available to the scientific community a new Flask
Flipper module, which has been designed to fit onto the company's
Freedom EVO liquid handling workstations.
Moving from egg-based production of vaccines to the use of
cell-culture technologies in existing manufacturing plants is
cheaper and quicker than building new facilities to handle a flu
pandemic within the next five years, new research...
Industrial enzyme maker Novozymes is seeking to strengthen its
presence in the biopharmaceutical market by offering to acquire
Australian biotechnology firm Gropep for AUD83.6m (€49.6m), eager
to become a supplier of recombinant ingredients...
The world's first drug made from a genetically engineered goat has
been given the thumbs up in Europe after being initially rejected
in February. The decision has reopened the door for "pharming,"
where transgenic animals...
Biocrystal has upped the stakes in the cell culture market with
Opticell, a product it claims brakes away from traditional cell
culture concepts and promises to reduce costs through increased
efficiency.
Surmodics has announced that as a result of a collaboration with
the Donaldson Company, the first of a collection of new synthetic
nanofibrillar cell culture surfaces have been produced that will
improve cell culture, cell-based bioassays...
Centocor has enlisted Cardinal Health to use its rapid cell line
development technology to engineer cell lines expressing Centocor's
monoclonal antibodies, and speed up the development of new
biopharmaceuticals.
Millipore has introduced a new 24-well cell culture plate which has
twice the membrane surface area compared with other 24-well plates,
allowing researchers to utilize greater cell mass, which more
closely models cell behaviour.
In the same week that saw Novartis threaten its planned merger with
Berna Biotech, Dutch biotech company Crucell has signed three new
licensing agreements for its PER.C6 and STAR manufacturing
technologies.
Dowpharma has announced the addition of an oligonucleotide
synthesizer for its manufacturing of nucleic acid medicines. The
new oligo synthesizer is said to increase speed and flexibility in
producing clinical quantities for customers.
Dublin City University in Ireland and pharmaceutical major Wyeth
have started a four-year research collaboration aimed at improving
the production of biopharmaceuticals, reports Phil Taylor.
Recently-formed cell culture specialist Celliance has introduced a
new supplement designed to boost the growth of cells used in
research and bioprocessing, that does not contain fetal bovine
serum.
Genetix Limited has launched the ClonePixFL, a mammalian cell
imaging and picking instrument that builds upon the success of the
ClonePix adding fluorescent capabilities to its clone picking
abilities.
Invitrogen announced it is to acquire Dynal Biotech, the molecular
separation and purification technology company. The deal will
provide Invitrogen with bead-based isolation technologies that
targets key medical research issues.
Australia's CSL, the world's largest manufacturer of blood plasma
products, has agreed to sell its JRH Biosciences division to
Sigma-Aldrich for $370 million (€283m) in cash. JRH makes cell
culture and sera products used...
US biotechnology start-up Cytovance Biologics has officially opened
for business this month, offering a portfolio of process
development services to support biotechnology companies preparing
to progress products into clinical development.
Cell culture equipment company Integra Biosciences has launched a
new roller system designed to improve the cultivation of adherent
and suspension cells.
Applying automation to tissue culture techniques can improve the
development, maintenance and expansion of mammalian cells,
increasing the efficiency of drug discovery efforts, reports Wai
Lang Chu.
Proliant Biologicals has launched a new cell culture medium that
can be used for the production of monoclonal antibodies and other
proteins but is claimed to be more economical than a rival product.
Lonza Biologics has licensed rights its proprietary CHOK1SV cell
line to Canadian firm Chromos Molecular Systems for a project aimed
at making improved mammalian cells for biological syntheses.
Contract research manufacturer Diosynth has forged a joint venture
with a Swiss firm for a technology that could dramatically reduce
the time and cost of developing new cell lines for manufacturing
proteins, writes Phil Taylor.
Fisher Scientific subsidiary Perbio last week opened a new facility
in the UK to manufacture its Hyclone range of cell culture
equipment and mediathat ramps up its liquid production capacity by
a factor of four, reports Phil Taylor.
Novartis' generic drugs subsidiary Sandoz has opened two new
manufacturing plants in Austria and Slovenia that mark its entry
into the contract manufacture of biopharmaceuticals using mammalian
cell culture.
A cell culture vessel designed by Taiwanese company CESCO
Bioengineering can produce the same amount of cells in a single
500ml bottle as would be made in 20 or more conventional roller
bottles, according to the company which is introducing...
Life sciences technology company Invitrogen has entered into a
definitive agreement to acquire fellow US firm BioReliance, which
specialises in the testing and manufacture of biologic drugs.
A US start-up company specialising in biomaterials, 3DMatrix, has
developed a synthetic scaffold product that can be used to create
self-assembling, microscale environments to encourage the growth of
cells in culture.
Dow Chemical has teamed up with Germany's greenovation Biotech to
develop ways of manufacturing therapeutic proteins such as
monoclonal antibodies in plants.
Switzerland's Integra Biosciences extends its CELLine range of
disposable bioreactor vessels with a new version intended for use
with adherent cell lines.
Guava technologies has developed a new assay system for counting
and viability testing of non-mammalian cells, including insect
cells used in vaccine research.
Swedish company Perbio Science has agreed to a $714 million (€626m)
takeover by Fisher Scientific International of the USA, which says
that it sees the acquisition as a means of capitalising on the
strong growth of the life science...
Crucell has granted a license for its PER.C6 cell line technology
to Novavax, allowing the latter company to start offering contract
manufacturing services for vaccines.